337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
The Readout Loud
00:00
Biotech M&A Dynamics at JPMorgan Conference
This chapter explores significant M&A activities in the biotech sector, focusing on Johnson & Johnson's $14.6 billion acquisition of Intracellular Therapies. It discusses market uncertainties and the mixed sentiments among industry leaders, highlighting the need for consolidation and the evolving role of AI in drug development.
Transcript
Play full episode
